AZ876

AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis[1][2].

Product Specifications

CAS Number

[898800-26-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

LXR

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer; Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/AZ876.html

Purity

99.77

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C(NC1=CC=C(N2CCCCC2)C=C1)=C3C4=CC=CC=C4)N(C(C)(C)C)S3(=O)=O

Molecular Formula

C24H29N3O3S

Molecular Weight

439.57

Precautions

H302, H315, H319, H335

References & Citations

[1]Ritter D, et al. Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenol-Induced Cardiac Damage. J Am Heart Assoc. 2021 Jul 20;10 (14) :e019473.|[2]van der Hoorn J et al. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. Br J Pharmacol. 2011 Apr;162 (7) :1553-63.